IL99401A - Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations - Google Patents

Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations

Info

Publication number
IL99401A
IL99401A IL9940191A IL9940191A IL99401A IL 99401 A IL99401 A IL 99401A IL 9940191 A IL9940191 A IL 9940191A IL 9940191 A IL9940191 A IL 9940191A IL 99401 A IL99401 A IL 99401A
Authority
IL
Israel
Prior art keywords
protein
nucleotide sequence
outer membrane
sequence coding
neisseria meningitidis
Prior art date
Application number
IL9940191A
Other languages
English (en)
Other versions
IL99401A0 (en
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of IL99401A0 publication Critical patent/IL99401A0/xx
Publication of IL99401A publication Critical patent/IL99401A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01004—Dihydrolipoyl dehydrogenase (1.8.1.4), i.e. lipoamide-dehydrogenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL9940191A 1990-09-07 1991-09-04 Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations IL99401A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU90145A CU22302A1 (es) 1990-09-07 1990-09-07 Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales

Publications (2)

Publication Number Publication Date
IL99401A0 IL99401A0 (en) 1992-08-18
IL99401A true IL99401A (en) 2003-12-10

Family

ID=5459451

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9940191A IL99401A (en) 1990-09-07 1991-09-04 Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations

Country Status (15)

Country Link
US (1) US5286484A (xx)
EP (1) EP0474313B1 (xx)
JP (1) JP3253327B2 (xx)
AR (1) AR245778A1 (xx)
AT (1) ATE152175T1 (xx)
AU (1) AU657487B2 (xx)
CA (1) CA2050749C (xx)
CU (1) CU22302A1 (xx)
DE (1) DE69125769T2 (xx)
ES (1) ES2103295T3 (xx)
FI (1) FI103511B1 (xx)
GR (1) GR3024127T3 (xx)
IL (1) IL99401A (xx)
NO (1) NO913524D0 (xx)
RU (1) RU2132383C1 (xx)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
AU2816095A (en) * 1994-06-24 1996-01-19 Children's Hospital Medical Center Escherichia coli o157:h7 epithelial adhesin
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
WO1998009990A1 (fr) * 1996-09-04 1998-03-12 Takara Shuzo Co., Ltd. Antigenes fongiques et processus de fabrication
WO1999036544A2 (en) * 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
KR20060118629A (ko) * 1998-04-29 2006-11-23 와이어쓰 홀딩스 코포레이션 나이제리아 고노리아 또는 나이제리아 메닌지티디스에 대한재조합 필린을 함유한 백신
JP5102414B2 (ja) * 1998-05-01 2012-12-19 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 髄膜炎菌抗原および組成物
US6756493B1 (en) * 1998-09-01 2004-06-29 Antex Biologics, Inc. Nucleic acid sequence and uses thereof
US6693186B2 (en) * 1998-09-01 2004-02-17 Antex Biologics Inc Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
EP1144998A3 (en) * 1998-10-09 2002-08-07 Chiron Corporation Neisseria genomic sequences and methods of their use
ES2310776T3 (es) * 1998-10-22 2009-01-16 The University Of Montana Composiciones de vacuna que comprenden proteinas omp de neisseria gonorrhoeae y de neisseria meningitidis.
US6610306B2 (en) 1998-10-22 2003-08-26 The University Of Montana OMP85 protein of neisseria meningitidis, compositions containing the same and methods of use thereof
CA2347849C (en) * 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
EP1939215A1 (en) 1998-10-22 2008-07-02 The University of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
MXPA02008314A (es) * 2000-02-28 2002-12-09 Chiron Spa Expresion heterologa de proteinas de neisseria.
EP1274732A1 (en) * 2000-04-20 2003-01-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Secretory tyrosine phosphatases from mycobacteria
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
AU2004236174B2 (en) 2001-10-10 2011-06-02 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
WO2004015099A2 (en) * 2002-08-02 2004-02-19 Glaxosmithkline Biologicals Sa Vaccine composition comprising lipooligosaccharide with reduced phase variability
CA2501812C (en) * 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
BR0316271A (pt) * 2002-11-14 2005-10-11 Inst Finlay Ct De Investigacio Método para a obtenção de preparados vacinais conjugados multivalentes, composição vacinal multivalente e uso da mesma
US7803777B2 (en) 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
CA2524936A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
MX2010009154A (es) 2008-02-27 2010-09-09 Novo Nordisk As Moleculas conjugadas del factor viii.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
RU2023448C1 (ru) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в

Also Published As

Publication number Publication date
FI914129A0 (fi) 1991-09-03
EP0474313A2 (en) 1992-03-11
EP0474313A3 (en) 1993-02-24
JP3253327B2 (ja) 2002-02-04
EP0474313B1 (en) 1997-04-23
ES2103295T3 (es) 1997-09-16
GR3024127T3 (en) 1997-10-31
CA2050749A1 (en) 1992-03-08
AU8368391A (en) 1992-03-12
RU2132383C1 (ru) 1999-06-27
JPH06169779A (ja) 1994-06-21
CA2050749C (en) 2002-07-02
AU657487B2 (en) 1995-03-16
DE69125769T2 (de) 1997-11-27
FI103511B (fi) 1999-07-15
NO913524D0 (no) 1991-09-06
CU22302A1 (es) 1995-01-31
US5286484A (en) 1994-02-15
FI914129A (fi) 1992-03-08
DE69125769D1 (de) 1997-05-28
IL99401A0 (en) 1992-08-18
FI103511B1 (fi) 1999-07-15
ATE152175T1 (de) 1997-05-15
AR245778A1 (es) 1994-02-28

Similar Documents

Publication Publication Date Title
GR3024127T3 (en) Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations
PL328096A1 (en) Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
PL312712A1 (en) High level expression, purification and repeated creasing of group b(porynowe?) proteins of outer membrane of neisseria meningitidis
DK392089A (da) Terapeutisk praeparat indeholdende fede syrer og f remgangsmaade til fremstilling heraf
NO891378L (no) Hudrensings- og fuktingspreparat og fremgangsmaate ved bruk og fremstilling derav.
GB2314013B (en) Integrated dental chair and post-mounted delivery system
AU8762991A (en) Human papilloma viral protein expression for use in vaccine compositions
EP0859627A4 (en) PEPTIDE MIMETICS IN CANCER THERAPY
PL325373A1 (en) Compounds and methods useful in tuberculosos immunotherapy and diagnostics
EP0693931A4 (en) IMMUNOGENIC PROTEINS AND PEPTIDES OF CANCER AND METHOD OF USE
IL93957A0 (en) Bordetella outer membrane proteins,their use in vaccines and their expression
EP0491844A4 (en) Peptides including ctl epitopes of hiv proteins and use thereof
AU6428890A (en) Therapeutic peptides and proteins
IL87391A0 (en) Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them
GB9516293D0 (en) Novel peptides and their use as vaccines
ZA904565B (en) Peptides and antibodies derived therefrom for the diagnosis of therapy for and vaccination against htlv-1 infection
DE69201351D1 (de) Molkeproteingel und Verfahren zu dessen Herstellung.
DK394889A (da) Vaccine til profylakse og kontrol af haemophilus pleuropneumoniae i svin samt fremgangsmaade til fremstilling af extracellulaert proteinmateriale fra h. pleuropneumoniae til anvendelse i saadanne vacciner
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
EE9800188A (et) N-atsetüül-(L)-4-tsüanofenüülalaniini Ac-(L)-Phe- (4-CN)-OH ja N-atsetüül- (L)-p-amidinofenüülalaniintsükloheksüülglütsiin-ß- (3-N-metüülpüridiinium)alaniini Ac-(L)-pAph-Chg-PalMe(3)-NH2 valmistamismeetod
IL98839A0 (en) Vaccines comprising protein of the outer membrane of neisseria meningitidis
EP0540575A4 (en) Human meg-csf protein and methods
IL98837A0 (en) Pharmaceutical compositions comprising proteins from the outer membrane of neisseria meningitidis and their use to increase the immune response
ITMI912837A0 (it) Procedimento per preparare prodotti peptidici e/o proteinici arricchiti con amminoacidi legati in modo covalente
NZ277605A (en) Human stanniocalcin-alpha polypeptide and dna (rna) encoding polypeptide; polypeptide may be derived from atcc 75861

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees